Tenders

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for the Active Ingredient Tafluprost Timolol, Atc S01ed51 for the Period 09/01/2023 - 08/31/2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Amifampridine, Atc N07xx05 for the Period September 1St, 2023 - August 31St, 2025

Conclusion of a Non-Exclusive Framework Contract for Test Engineering Services in the Open House Procedure of the Rhineland Branch, Published in 2023

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Lanreotide (Atc Code: H01cb03).

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Dabigatran, Atc B01ae07 for the Period September 1St, 2023 - August 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Glecaprevir and Pibrentasvir, Atc J05ap57 for the Period 09/01/2023 - 08/31/2025

Conclusion of a Non-Exclusive Framework Contract for Test Engineering Services in the Open House Procedure of the Rhineland Branch, Published in 2023

Oh-Biologika-2023-21 - Teriparatids

Open House Drug Rebate Contracts Nilotinib, Atc L01ea03

Finished Medicinal Product Called Itulazax (Atc: V01aa05 - Tree Pollen)